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Introduction 
Testicular cancer is a relatively rare 
cancer with an estimated 8,290 new cases 
diagnosed annually in the US.1 Germ cell 
carcinomas comprise the overwhelming 
majority (98.9%) of adult testicular carci-
nomas.2 Ninety-five percent of germ cell 
tumors (GCTs) occur in the gonads and the 
rest occur in extragonadal tissues.3 
Germ cell tumors are divided into 
seminomatous or non-seminomatous types.4 
Non-seminomatous germ cell tumors 
(NSGCT) may be composed of embryonal 
carcinoma, teratoma, choriocarcinoma, or 
yolk sac tumors. Ninety percent of non-
seminomatous tumors express either alpha-
fetoprotein or human chorionic gonado-
trophin (hCG).5 Intact hCG consists of two 
subunits. The α subunit is identical to the α 
subunit of the pituitary gonadotrophins and 
thyroid-stimulating hormone (TSH). The β 
subunit is unique to hCG, but strongly 
resembles the β subunit of luteinizing 
hormone (LH). Beta-hCG levels are an 
important tool in the diagnosis and 
monitoring of treatment of NSGCT. Studies 
in animals and humans showed that hCG can 
activate the TSH receptor when present in 
excess and induce thyrotoxicosis.6,7 More 
than 40% of patients with beta-HCG in 
excess of 50,000 U/L have biochemical 
hyperthyroidism.8  
We report a male patient presenting with 
metastatic extragonadal germ cell tumor 
EGCT) who developed thyrotoxicosis. 
Case Report 
A 38-year-old male, without significant 
past medical history, presented with 
complaints of shortness of breath, 
hemoptysis, and night sweats of two-month 
duration. A chest x-ray showed diffuse 
pulmonary nodules confirmed on a 
subsequent chest computed tomography (CT) 
scan. In addition, an anterior mediastinal 
mass was identified on CT. A CT guided 
biopsy of the anterior mediastinal mass was 
performed.  Based on the morphology and 
immune profile, this mass was classified as 
NSGCT with a predominant choriocarcinoma 
component.  Staging revealed metastases to 
the brain, liver, spleen, and kidney. 
Testicular ultrasound did not reveal any 
masses, thus making the diagnosis of an 
extragonadal germ cell tumor (EGCT). A 
serum beta-hCG level was found to be 
greater than 200,000 U/L. 
During this hospital admission in which 
chemotherapy was initiated, the patient 
developed persistent tachycardia and fever.  
In light of his known elevated beta-hCG 
level, a diagnosis of paraneoplastic hyper-
thyroidism with impending thyroid storm 
was entertained. Thyroid testing revealed a 
TSH of 0.071 mcu/mL (0.35-5.0), total T3 of 
231 ng/dL (80-180), and a free thyroxine 
level of 3.0 ng/dL (0.6-1.6). Although the 
patient’s thyrotoxicosis was suspected to be 
related to hCG induced hyperthyroidism, 
additional testing was undertaken to rule out 
an   autoimmune  etiology  of  thyrotoxicosis,  
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including measurement of thyroid peroxidase 
antibodies (TPO) and thyroid stimulating 
immunoglobulins (TSI).  Both TPO and TSI 
testing were normal thus ruling out 
Hashimoto’s thyrotoxicosis and Grave’s 
hyperthyroidism as potential etiologies.  
Radioactive iodine uptake and scanning was 
not pursued due to recent iodine loading with 
CT contrast material.  
Due to symptomatic hyperthyroidism, the 
patient was initiated on anti-thyroid 
medication and propranolol. He received two 
cycles of a chemotherapeutic regimen 
including ifosfamide, paclitaxel, and cis-
platin. Within days of initiating chemo-
therapy, his symptoms of thyrotoxicosis 
resolved and his free thyroxine normalized.  
His anti-thyroid medication and propranolol 
were rapidly tapered off. His beta-HCG level 
dropped to 148,047 U/L after the first cycle 
of chemotherapy and eventually to a nadir of 
401 U/L.  Upon review of serial values of β-
HCG, free thyroxine, and TSH measure-
ments, there was an obvious improvement in 
thyroid laboratory testing with decreasing β-
hCG levels (see Figure 1). Unfortunately, the 
patient had further oncologic disease 
progression with poor response to additional 
cycles of cisplatin based chemotherapy.  He 
expired within eight months of initial 
diagnosis.  
 
Discussion 
Paraneoplastic hyperthyroidism can occur 
in non-seminomatous germ cell tumors due 
to the choriocarcinoma component of these 
tumors which produces hCG. hCG has 
thyroid stimulating activity in animals as 
well as humans.9  In patients with NSGCT, 
the prevalence of hyperthyroidism in a large 
cohort study was 3.5%.10   Within this same 
cohort, the prevalence of hyperthyroidism 
increased to 50% in patients with high serum 
hCG levels at presentation (>50,000 IU/L).10 
Not all patients with significantly elevated 
hCG levels develop hyperthyroidism; this is 
thought to be related to the existence of hCG 
variants with different isoforms having 
different thyroid stimulating activity.9,11 
Another potential explanation for the 
disparate development of paraneoplastic 
hyperthyroidism may be the presence of 
polymorphisms of the TSH receptor gene, 
resulting in increased sensitivity of the TSH 
receptor to hCG.12 
hCG induced hyperthyroidism has been 
reported more commonly in women.13 
Gestational transient thyrotoxicosis can be 
seen in women with high serum 
concentration of hCG during early pregnancy 
leading to hyperthyroidism characterized by 
elevated serum free thyroxine concentrations 
and low serum TSH concentrations. hCG 
related hyperthyroidism can be seen in 
women with gestational trophoblastic disease 
(GTD); the development of hyperthyroidism 
in this population is influenced largely by the 
level of hCG as well.14  
Standardized recommendations for 
treatment of hCG induced hyperthyroidism 
in patients with testicular cancer do not 
exist.15 Patients with symptomatic hyper-
thyroidism are treated with β adrenergic 
receptor antagonist therapy and/or anti-
thyroid drugs.16 Anti-thyroid medications are 
an efficacious adjuvant treatment in hCG 
induced hyperthyroidism since hormone 
synthesis occurs within the thyroid gland. 
However, hyperthyroidism in hCG secreting 
malignant disease represents a paraneoplastic 
syndrome, therefore, the definitive treatment 
is treatment of the cancer. 
 
Conclusion 
 hCG induced hyperthyroidism in GCTs 
can be overlooked as the signs and symptoms 
of hyperthyroidism may be attributed to the 
underlying malignancy and treatment of the 
same. In patients with NSGCT and hCG 
levels greater than 50,000, screening for 
thyroid dysfunction should be undertaken 
given the high prevalence of paraneoplastic
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Figure 1.  β-HCG, free thyroxine, and TSH measurements over time. 
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hyperthyroidism in this cohort. Paraneo-
plastic hyperthyroidism can be managed with 
anti-thyroid medications as well as symp-
tomatic therapy with β-adrenergic receptor 
antagonists.  However, definitive treatment 
lies in treating the underlying malignancy. 
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